نتایج جستجو برای: Intermediate thalassemia

تعداد نتایج: 151460  

Journal: :iranian journal of blood and cancer 0
azamsadat hashemi mahboobeh abrishamkar ali reza jenabzade ziae eslami

background: hydroxyurea (hu) is a well known chemotherapeutic agent that has been used largely for various myeloproliferative diseases over the past 20 years. in β-thalassemia, the effect of hu is much less clear and remains controversial. this study was undertaken to describe the hematologic and clinical responses of thalassemia major and intermediate patients to hu treatment during 2 years. m...

Journal: :iranian journal of pathology 2006
madjid qolipour peinavandi maliheh khoddami

spinal cord compression due to extramedullary hematopoiesis is a well-described and rare syndrome encountered in several hematological disorders including β-thalassemia. hereby, a 37-year old pregnant woman with intermediate β -thalassemia with paraparesis and lower limb hypoesthesia was presented. mri showed soft tissue masses in both sides of thoracic paraspinal area. histologically, a mixtur...

Journal: :iranian biomedical journal 0
majid motovali-bashi tayyebeh ghasemi

background: &beta-thalassemia; is the most common monogenic disorder in human. the (ct) polymorphism at -158 upstream region of the &gammag-globin; gene and pharmacological factors such as hydroxyurea have been reported to influence &gamma-globin; gene expression and the severity of clinical symptoms of &beta-thalassemia.; methods: in the present study, 51 &beta-thalassemia; intermediate patie...

Journal: :iranian journal of blood and cancer 0
keikhaei b hirad far a abolghasemi h mousakhani h ghanavat m moghadam m

background: transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. alloimmunization is an unwanted side effect of blood transfusion. the present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in southwest iran. patients and methods: this was a cross-s...

Ali Reza Jenabzade, Azamsadat Hashemi, Mahboobeh Abrishamkar, Ziae Eslami,

Background: Hydroxyurea (HU) is a well known chemotherapeutic agent that has been used largely for various myeloproliferative diseases over the past 20 years. In β-thalassemia, the effect of HU is much less clear and remains controversial. This study was undertaken to describe the hematologic and clinical responses of thalassemia major and intermediate patients to HU treatment during 2 years. M...

Abolghasemi H, DorAli Nabi N, Falsafi-Zadeh S, Ghanavat M, Ghasem Zadeh A, Hirad Far A, Karimi Z, Keikhaei B, Moghadam M, Mousakhani H,

Background: Transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. Alloimmunization is an unwanted side effect of blood transfusion. The present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in Southwest Iran. Patients and Methods: This was a cross-...

Journal: :مجله دانشگاه علوم پزشکی کرمانشاه 0
hooshang nemati ms in biochemistry, kermanshah university of medical sciences zohreh rahimi assistant professor in biochemistry, kermanshah university of medical sciences. gholam reza bahrami associate professor in pharmacology, kermanshah university of medical sciences hamid nomani assistant professor in biochemistry, kermanshah university of medical sciences mansour rezaei assistant professor in biostatistics, kermanshah university of medical sciences

introduction: beta thalassemia is the most common inherited bloody disorder, affecting synthesis of the beta globin chain of hemoglobin. the type of β-thalassemia mutation affects on the β-globin chain synthesis that appears as β ° ، β + and β ++ -thalassemia. the presence of xmni polymorphic site at the 5 َ region of the g γ-globin gene affects on the rate of g γ chain synthesis and in some con...

Journal: :international journal of hematology-oncology and stem cell research 0
ebrahim miri-moghaddam associate professor, ph.d in human molecular genetics, department of genetics, faculty of medicine, birjand university of medical sciences, birjand, iran sara bahrami msc in biology, department of biology, payame noor university, iran majid naderi associate professor, genetics of non-communicable disease research center, department of pediatric hematology & oncology, faculty of medicine, zahedan university of medical sciences, zahedan, iran ali bazi msc in hematology, faculty of allied medical sciences, zabol university of medical sciences, zabol, iran morteza karimipoor ph.d, molecular medicine department, biotechnology research center, pasteur institute of iran, tehran, iran

background: xmn-1 polymorphism of

Journal: :international journal of hematology-oncology and stem cell research 0
ebrahim miri-moghaddam sara bahrami majid naderi ali bazi morteza karimipoor

background: xmn-1 polymorphism of y g globin gene ( hbg2 ) is a prominent quantitative trait loci (qtl) in β-thalassemia intermediate (β-ti). in current study, we evaluated frequency of xmn-1 polymorphism and its association with β-globin gene ( hbb ) alleles and hb f level in β-ti patients in sistan and balouchestan province, south-east of iran. methods: 45 β-ti patients were enrolled. hbb gen...

جمالی , مانی, وحیدشاهی , کوروش, کرمی , حسن, کرمی , حسین, کوثریان , مهرنوش,

Background and Purpose: Cholelithiasis is a common problem among patients with homozygous major and intermediate β-thalassemia due to chronic hemolysis, ineffective erythropoesis and other factors that causes variety of side effects. Hydroxyurea (HU) decreases hemolysis by increasing HbF production in homozygous β-thalassemia patients. Up to now, there have not been evidences about relationsh...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید